medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2016, Number 620

<< Back Next >>

Rev Med Cos Cen 2016; 73 (620)

Utilidad del octreótido en el tratamiento de fistulas enterocutáneas de intestino

Sánchez AM

Language: Spanish
References: 16
Page: 547-553
PDF size: 221.57 Kb.


ABSTRACT

We had have times when we dispose Parenteral Nutrition (PN) and Octreotide (Oct) for the fistulas treatment but others tiemes we had only PN. That fact gave us the opportunity to study those two groups and evaluated the efficacy of the Oct. We studied 55 patients, 39 received PN+Oct, 16 patients received only PN. All patients had small bowel fistulas. The proportion between benign and malignant pathology wrere similar. The 72.7% of fistulas were of low output ( less than 500 cc/day). There were no mortality. The 74% of patients who received PN+Oct resolved their fistula in 16 days meanwhile the 75% of patients who received only PN resolved the fistula in 14 days. Conclusion: Because of that numbers we concluded that Octreotide for the treatment of fistulas of the small bowel do not added any benefit


REFERENCES

  1. Alfaro. R. Abordaje de la fístula enterocutánea postoperatoria. Revista médica de Costa Rica y Centroamérica 2010 LXVII. (595): 455-460

  2. Alvarez C, Mc Fadden D. Complicated Enterocutaneous fistulas: failure of Ocreotide to improve healing. World J Surg. ; vol 24 (5): 533-538

  3. Arenas. H, Anaya. R, Minguía. D, Barrera. L, Arenas. D, Chávez. R. Fístula enterocutánea vrs fuga de anastomosis postoperatoria. Revista Cirujano General 2009 Vol 31 Supl 1:68-78.

  4. Arenas. H, Anaya. R. Nutrición Enteral y Parenteral. Fístulas Gastrointestinales. Editorial Mc Graw Hill. México 2012: 372-383

  5. Dominguez. L , Sanabria. A, Valentín. N , Osorio. C. . ¿Son útiles la somatostatina y sus análogos (octreótido y lantreótido) en el manejo del paciente con fístula entero-cutánea? Rev Colomb Cir. 2010;25:202-11.

  6. Ferrer. M, Virgili. N I Curso Sénior de Nutrición de la SEEN. Pauta nutricional en una fístula enterocutánea. Revista Endocrinología y Nutrición 2007 Vol 54 Supl 2: 48-53

  7. Irles. J, Torres. C. Fístula enteral manejo clínico. Revista Nutrición clínica en medicina 2008 Vol II N 1:12-22.

  8. Majercik D. Kinikini M., Wlhite T.. Enteroatmospheric fistula: From _Soup To Nuts . Nutrition and Clinical Practice 2012 Vol 27, N 4: 507-512

  9. Martínez. J, Luque de León. E, Suárez. R, Blanco. R. Fístulas enterocutáneas postopertorias. Revista Gaceta Médica de Mé Majercik. S, Kinikini. M, White.T. Enteroatmospheric Fistula: From Soup to Nuts. Nutrition and Clinical Practice 2012 Vol 27. N 4: 507-512.

  10. Mustafa. G, Rehman. M, Muhammad. K, Sadig. W. Enterocutaneus high output fistula, octreotide an effective tool in management. Profesional Med J. 2010 Vol 17 N 4:538-542.

  11. Njeze G.E, Achebe UJ. http:www. njcponline.com on Monday 27, 2015, IP: 201. 199101.3

  12. Pickhardt. P, Bhalla. S, Balfe. D. . Acquired Gastrointestinal Fistulas: Classification, Etiologies, and Imaging Evaluation. Radiology 2002 Vol 224 N 1: 9-23

  13. Rajan. C. . The Challenge of enterocutaneous Fistulae. MJAFI. 2004 Vol 60 N 3: 235-238.

  14. Schecter W. Managment of Enterocutaneous fistulas. Surg. Clin N Am 2011: 481-491

  15. Stevens P, Feulkes R. Systematic review nad meta analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula European Journal of Gastroenterology and Hepatology 2011; vol 23 (10): 912-922.

  16. Vincench. M, Pérez. A, Morales. A. Nuevos enfoques en el tratamiento de las fístulas enterocutáneas. Correo Científico Médico 2012 Vol 16 N 1.




2020     |     www.medigraphic.com